Related Experiment Video

Updated: May 17, 2026

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

Plasmacytoid dendritic cells: biomarkers or potential therapeutic targets in atherosclerosis?

Gianluca Grassia1, Neil MacRitchie, Andrew M Platt

  • 1Department of Experimental Pharmacology, University of Naples Federico II, 80131 Naples, Italy.

Pharmacology & Therapeutics
|October 13, 2012
PubMed

Insights

Plasmacytoid dendritic cells (pDCs) are linked to vascular pathology in autoimmune diseases. Research is exploring their role in atherosclerosis and potential therapeutic targeting.

Area of Science:

  • Immunology
  • Cardiovascular Research
  • Autoimmune Diseases

Background:

  • Plasmacytoid dendritic cells (pDCs) are crucial immune cells involved in autoimmune diseases.
  • pDCs are found in atherosclerotic plaques, and low circulating pDC levels correlate with cardiovascular events.

Purpose of the Study:

  • To review the role of pDCs in immunity and vascular pathology.
  • To discuss the contribution of pDCs to atherosclerosis in chronic inflammatory autoimmune diseases.
  • To explore therapeutic strategies targeting pDCs.

Main Methods:

  • Literature review of clinical studies and mouse models.
  • Analysis of the role of pDCs in innate and adaptive immunity.
  • Examination of evidence linking pDCs to vascular pathology and atherosclerosis.

Main Results:

  • pDCs are implicated in the pathogenesis of vascular pathology associated with autoimmune diseases.
  • Mouse models are beginning to elucidate the specific functions of pDCs in disease progression.
  • A potential association between pDCs and the acceleration of atherosclerosis is emerging.

Conclusions:

  • pDCs play a significant role in the immune response and vascular pathology.
  • Further research is needed to clarify the causal relationship between pDCs and atherosclerosis.
  • Targeting pDCs may offer a novel therapeutic approach for autoimmune diseases with vascular complications.

More Related Videos

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients09:09

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients

Published on: April 3, 2026

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors13:34

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors

Published on: March 17, 2014

Related Concept Videos

Inflammation01:38

Inflammation

Overview
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...